Bellerophon Therapeutics, Inc. 0HMP.L Stock
Bellerophon Therapeutics, Inc. Price Chart
Bellerophon Therapeutics, Inc. 0HMP.L Financial and Trading Overview
| Bellerophon Therapeutics, Inc. stock price | 0.06 USD |
| Previous Close | 0.73 USD |
| Open | 0 USD |
| Bid | 0 USD x N/A |
| Ask | 0 USD x N/A |
| Day's Range | 0 - 0 USD |
| 52 Week Range | 0 - 12.35 USD |
| Volume | 3.8K USD |
| Avg. Volume | 2.31K USD |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.895847 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.885 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0HMP.L Valuation Measures
| Enterprise Value | -7500614 USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.7026305 |
| Enterprise Value/Revenue | -1.33 |
| Enterprise Value/EBITDA | 0.493 |
Trading Information
Bellerophon Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.895847 |
| 52-Week Change | -48.41% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12.35 USD |
| 52 Week Low | 0 USD |
| 50-Day Moving Average | 7.25 USD |
| 200-Day Moving Average | 5.87 USD |
0HMP.L Share Statistics
| Avg. Volume (3 month) | 2.31K USD |
| Avg. Daily Volume (10-Days) | 6.62K USD |
| Shares Outstanding | N/A |
| Float | 7.05M |
| Short Ratio | N/A |
| % Held by Insiders | 4.11% |
| % Held by Institutions | 44.42% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 0.066667:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -201.56% |
| Operating Margin (ttm) | -270.70% |
| Gross Margin | 100.00% |
| EBITDA Margin | -269.91% |
Management Effectiveness
| Return on Assets (ttm) | -50.60% |
| Return on Equity (ttm) | -84.92% |
Income Statement
| Revenue (ttm) | 5.64M USD |
| Revenue Per Share (ttm) | 0.58 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -15223000 USD |
| Net Income Avi to Common (ttm) | -11368000 USD |
| Diluted EPS (ttm) | -1.885 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 15.17M USD |
| Total Cash Per Share (mrq) | 1.45 USD |
| Total Debt (mrq) | 8K USD |
| Total Debt/Equity (mrq) | 0.08 USD |
| Current Ratio (mrq) | 2.94 |
| Book Value Per Share (mrq) | 1.015 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -9768000 USD |
| Levered Free Cash Flow (ttm) | -8167500 USD |
Profile of Bellerophon Therapeutics, Inc.
| Country | United Kingdom |
| State | NJ |
| City | Warren |
| Address | 20 Independence Boulevard |
| ZIP | 07059 |
| Phone | (908) 574-4770 |
| Website | https://bellerophon.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 18 |
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Q&A For Bellerophon Therapeutics, Inc. Stock
What is a current 0HMP.L stock price?
Bellerophon Therapeutics, Inc. 0HMP.L stock price today per share is 0.06 USD.
How to purchase Bellerophon Therapeutics, Inc. stock?
You can buy 0HMP.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bellerophon Therapeutics, Inc.?
The stock symbol or ticker of Bellerophon Therapeutics, Inc. is 0HMP.L.
How many shares does Bellerophon Therapeutics, Inc. have in circulation?
The max supply of Bellerophon Therapeutics, Inc. shares is 0.
What is Bellerophon Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Bellerophon Therapeutics, Inc. PE Ratio is now.
What was Bellerophon Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Bellerophon Therapeutics, Inc. EPS is -1.885 USD over the trailing 12 months.